Green Light for HLB's Liver Cancer Drug NDA Resubmission as FDA Completes Inspection of Finished Dosage Facility
cGMP Inspection of Manufacturing Facility Classified as 'VAI'
Elevar Finalizing Documents for Resubmission
HLB announced on October 6 that the U.S. Food and Drug Administration (FDA) has classified the routine cGMP inspection of the manufacturing facility for the finished dosage form of Rivoceranib as “Voluntary Action Indicated (VAI).”
HLB's U.S. subsidiary, Elevar Therapeutics, received a close-out letter regarding the inspection from its partner, Jiangsu Hengrui Pharmaceuticals, on October 3. As a result, it was confirmed that the FDA’s routine cGMP inspection of the Rivoceranib finished dosage manufacturing facility has been officially completed with a VAI classification.
VAI is a classification given when certain issues are identified during an FDA inspection, but the company is deemed capable of addressing them voluntarily, so no formal regulatory action is required.
Elevar is currently finalizing the documents required to resubmit the New Drug Application (NDA) for liver cancer in collaboration with Jiangsu Hengrui Pharmaceuticals. Once preparations are complete, the company plans to resubmit the NDA to the FDA.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An HLB official stated, "This VAI classification is a result of Jiangsu Hengrui Pharmaceuticals mobilizing its entire organizational capabilities to actively address the findings from the inspection. Elevar will work closely with Jiangsu Hengrui Pharmaceuticals to expediently complete the preparations for the NDA resubmission for liver cancer, and thereafter, respond seamlessly to the subsequent FDA review."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.